Comparing the Differential Diagnostic Values of 18F-Alfatide II PETCT between Tuberculosis and Lung Cancer Patients

Abstract EN

Purpose.

To compare the differential diagnostic values of 18F-Alfatide II PET/CT between tuberculosis and lung cancer patients and in patients with sarcoidosis and common inflammation.

Methods.

Nine inflammation patients (4 tuberculosis, 3 sarcoidosis, and 2 common inflammation) and 11 lung cancer patients were included in this study.

All patients underwent 18F-FDG and 18F-Alfatide II PET/CT within 2 weeks, followed by biopsy and surgery.

The maximized standard uptake value (SUVmax) and the mean standard uptake value (SUVmean) were evaluated.

Results.

The active tuberculosis lesions showed a high accumulation of 18F-FDG, but varying degrees of accumulation of 18F-Alfatide II, including negative results.

The SUVmax of 18F-Alfatide II in malignant lesions was significantly higher than that in tuberculosis (4.08 ± 1.51 versus 2.63 ± 1.34, P = 0.0078).

Three patients with sarcoidosis showed negative results in 18F-Alfatide II PET/CT.

Conclusions.

The expression of αVβ3 is much lower in tuberculosis as compared to that in lung cancer, and accumulation of 18F-Alfatide II varied even in lesions of the same patient.

The negative results of sarcoidosis patients led to the speculation that αVβ3 was not expressed in those lesions.